Observational studyPloS one2025
Effects of cutaneous leishmaniasis on health-related quality of life: A longitudinal approach.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Cutaneous leishmaniasis impact questionnaire: Translation, cross-cultural adaptation and validation in adults with Cutaneous leishmaniasis in Ethiopia.PLoS neglected tropical diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCutaneous leishmaniasis (CL) is a neglected tropical disease that significantly affects patients' physical, psychological, and social well-being. Although previous studies have documented health-related quality of life (HRQoL) impairments associated with CL, most have relied on cross-sectional data, providing only a snapshot of the disease burden. Few studies have examined HRQoL progression over time or explored treatment effects from the patient's perspective.
objectivesThis study aimed to evaluate changes in HRQoL among CL patients at three time points: before treatment, during treatment, and after treatment, using the Cutaneous Leishmaniasis Impact Questionnaire (CLIQ).
methodsA longitudinal observational study was conducted from October 2020 to April 2023 at a specialized center in Belo Horizonte, Brazil, involving 143 CL patients. The CLIQ was administered at diagnosis, during treatment (up to 30 days post-treatment), and at least 90 days after treatment initiation. Analyses included descriptive statistics, group comparisons using nonparametric methods, and correlation assessments based on rank-order relationships.
findingsOf the 143 patients enrolled, 120 completed all assessments. Median CLIQ scores improved significantly from pre-treatment (24, IQR 16-36) to post-treatment (15, IQR 8.25-25; p < 0.001). Notable improvements were observed in physical symptoms, emotional distress, and daily functioning. However, financial burden and social isolation persisted after treatment. Patient dissatisfaction with health services peaked during treatment but decreased afterward.
conclusionTreatment significantly enhanced HRQoL in CL patients, particularly in the physical and functional domains. Nevertheless, persistent financial and emotional challenges underscore the need for comprehensive support interventions addressing economic and psychosocial dimensions, thereby promoting holistic care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.